Interscalene Block Versus Combined Infraclavicular-Anterior Suprascapular Blocks for Shoulder Surgery
Launched by UNIVERSITY OF CHILE · Jul 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two different types of nerve blocks used for pain relief after shoulder surgery. The standard method, called the interscalene block (ISB), can sometimes cause breathing issues due to diaphragm paralysis. This trial aims to see if a new combination of nerve blocks, known as the combined infraclavicular-anterior suprascapular nerve blocks (ICB-ASSNB), can provide similar pain relief without the risk of breathing problems. Researchers are hoping that the new method will be just as effective for managing pain after surgery.
The trial is currently looking for participants who are undergoing arthroscopic shoulder surgery and are generally healthy (classified as American Society of Anesthesiologists classes 1-3) with a body mass index between 20 and 35. Those who are pregnant, have certain health conditions, or have specific allergies will not be eligible to participate. If you join the trial, you can expect to receive one of the two nerve blocks and will be monitored for pain relief and any side effects. This study is important because finding a safer method for pain management can greatly improve recovery experiences for patients with shoulder surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing arthroscopic shoulder surgery
- • American Society of Anesthesiologists classification 1-3
- • Body mass index between 20 and 35 kg/mt2
- Exclusion Criteria:
- • Adults who are unable to give their own consent
- • Pre-existing neuropathy (assessed by history and physical examination)
- • Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)
- • Obstructive or restrictive pulmonary disease (assessed by history and physical examination)
- • Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
- • Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
- • Allergy to local anesthetics (LAs)
- • Pregnancy
- • Prior surgery in the neck or infraclavicular region
- • Chronic pain syndromes requiring opioid intake at home
About University Of Chile
The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago, Metropolitana, Chile
Patients applied
Trial Officials
Julián Aliste, MD
Principal Investigator
University of Chile
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials